POLITICO ∙ 05/24/2021 ∙ Division of Preclinical Innovation
Coronavirus vaccines have reached American adults in record time, but the development of treatments for Covid-19 is stagnating — threatening efforts to stamp out clusters of infection and end the pandemic. Researchers say the lack of enough drugs for mildly ill patients means that the world may never completely stamp out the virus.
The tricky aspect is making sure that the drug works only in the virus — and doesn’t thwart healthy cells. “It needs to be exquisitely selective for just the target,” said Matthew D. Hall, Ph.D., a biologist in the Early Translation Branch of NCATS’ Division of Preclinical Innovation.